Gilead Sciences is trading at $173.61, up 3.67% in pre-market; no confirmed company-specific catalyst surfaced for the November 4 move.
- October 29 results: $8.3 billion in third-quarter product sales; Gilead raised its 2026 product-sales outlook. That earlier news is not a confirmed catalyst.
- The S&P 500 and Dow were higher, a possible broader-market backdrop, but no direct cause was established. No trading-volume details were provided.